Characterization of a hyaluronic acid and folic acid-based hydrogel for cisplatin delivery: Antineoplastic effect in human ovarian cancer cells in vitro

Int J Pharm. 2021 Sep 5:606:120899. doi: 10.1016/j.ijpharm.2021.120899. Epub 2021 Jul 27.

Abstract

We successfully prepared and characterized a hyaluronic acid- and folic acid-based hydrogel for the delivery of cisplatin (GEL-CIS) with the aim to induce specific and efficient incorporation of CIS into ovarian cancer (OC) cells, improve its antineoplastic effect and avoid CIS-resistance. The slow and controlled release of the drug from the polymeric network and its swelling degree at physiologic pH suggested its suitability for CIS delivery in OC. We compared here the effects of pure CIS to that of GEL-CIS on human OC cell lines, either wild type or CIS-resistant, in basal conditions and in the presence of macrophage-derived conditioned medium, mimicking the action of tumor-associated macrophages in vivo. GEL-CIS inhibited OC cell growth and migration more efficiently than pure CIS and modulated the expression of proteins involved in the Epithelial Mesenchymal Transition, a process playing a key role in OC metastatic spread and resistance to CIS.

Keywords: Carrier delivery; Cisplatin; Epithelial-Mesenchymal Transition; Folic acid; Hyaluronic acid; Hydrogel; Ovarian Cancer.

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Cell Line, Tumor
  • Cisplatin / pharmacology
  • Cisplatin / therapeutic use
  • Drug Resistance, Neoplasm
  • Female
  • Folic Acid / pharmacology
  • Humans
  • Hyaluronic Acid / pharmacology
  • Hydrogels / pharmacology
  • Ovarian Neoplasms* / drug therapy

Substances

  • Antineoplastic Agents
  • Hydrogels
  • Hyaluronic Acid
  • Folic Acid
  • Cisplatin